EGFR and non-small cell lung carcinoma: In the IMpower130 trial, as first-line treatment, atezolizumab plus chemotherapy resulted in an improvement in OS and PFS without new safety concerns compared with chemotherapy alone for patients with stage IV non-squamous NSCLC without ALK or EGFR mutations (28).